Monopar Therapeutics (MNPR) Expected to Announce Earnings on Thursday

Monopar Therapeutics (NASDAQ:MNPR) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.8231) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 17, 2026 at 12:30 PM ET.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.02. On average, analysts expect Monopar Therapeutics to post ($2.98) EPS for the current fiscal year and ($4.29) EPS for the next fiscal year.

Monopar Therapeutics Trading Up 3.3%

MNPR stock opened at $73.75 on Tuesday. The business’s fifty day simple moving average is $86.12 and its two-hundred day simple moving average is $77.41. Monopar Therapeutics has a twelve month low of $50.07 and a twelve month high of $124.82.

Insider Buying and Selling

In other Monopar Therapeutics news, CEO Chandler Robinson sold 29,056 shares of the company’s stock in a transaction that occurred on Thursday, September 24th. The stock was sold at an average price of $88.00, for a total value of $2,556,928.00. Following the sale, the chief executive officer owned 99,267 shares in the company, valued at approximately $8,735,496. This represents a 22.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total transaction of $351,181.34. Following the sale, the director directly owned 23,751 shares in the company, valued at $2,654,649.27. The trade was a 11.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 51,920 shares of company stock valued at $4,527,913. Insiders own 9.70% of the company’s stock.

Analyst Upgrades and Downgrades

MNPR has been the topic of a number of research reports. Morgan Stanley reaffirmed an “overweight” rating and set a $130.00 target price on shares of Monopar Therapeutics in a research report on Monday, August 17th. Barclays reissued an “overweight” rating and set a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a research report on Friday, September 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. UBS Group set a $125.00 price target on Monopar Therapeutics in a research report on Thursday, July 23rd. Finally, Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Monopar Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $122.78.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.